Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer’s disease (Aβ 42/40 ratio, P-Tau181). The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.